Growth
PEG-MGF
PEGylated peptide · IGF-1 splice variant · Extended half-life
FDA · CATEGORY 2 (2023)
Half-life
~2.5 days
Long
minsdays
Route
SubQ injection
Evidence
Preclinical only
Risk
Standard
Overview
Known for
Mechanism
Key facts
Format
Lyophilized powder
Mechanism targets
Classification
Secondary
Supply & nature
ExogenousExogenous
FDA category
Category 2 (2023)
Evidence & standing
Evidence base
Preclinical only
Risk level
Standard
Best studies
4 references
Dosage & protocol
Typical dose
200mcg
Research range
100–200 µg
Cycle
4 weeks on / 4 weeks off
Onset
21 days first effects
Full effect
49 days
Half-life
~48-72h
PEGylation extends native MGF half-life from ~5-7 min to ~48-72h in experimental models
Protocol
Time to effects
Recommended vial
Reference figures only
Dosing reflects published laboratory protocols and is not guidance for use in any living subject.
Safety
Handle with research caution
Storage & handling
Lyophilised
12–24 months
2–8°C
Reconstituted
3–4 weeks
2–8°C
